Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07307768
PHASE1

Ketamine Biomarker Validation

Sponsor: Soterix Medical

View on ClinicalTrials.gov

Summary

We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.

Official title: EEG Biomarker Development for Ketamine Administration

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-12-20

Completion Date

2028-03-01

Last Updated

2025-12-29

Healthy Volunteers

No

Interventions

DRUG

Ketamine (0.25 mg/kg)

Low level ketamine infusion therapy.

DRUG

Ketamine (0.5 mg/kg)

Medium level ketamine infusion therapy.

DRUG

Ketamine (0.75 mg/kg)

High level ketamine infusion therapy.

Locations (1)

Columbia University Irving Medical Center

New York, New York, United States